The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Leishmaniasis, Cutaneous

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Leishmaniasis, Cutaneous


High impact information on Leishmaniasis, Cutaneous


Chemical compound and disease context of Leishmaniasis, Cutaneous


Biological context of Leishmaniasis, Cutaneous


Anatomical context of Leishmaniasis, Cutaneous


Gene context of Leishmaniasis, Cutaneous



Analytical, diagnostic and therapeutic context of Leishmaniasis, Cutaneous


  1. Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. Von Stebut, E., Ehrchen, J.M., Belkaid, Y., Kostka, S.L., Molle, K., Knop, J., Sunderkotter, C., Udey, M.C. J. Exp. Med. (2003) [Pubmed]
  2. Cytokine patterns in the pathogenesis of human leishmaniasis. Pirmez, C., Yamamura, M., Uyemura, K., Paes-Oliveira, M., Conceição-Silva, F., Modlin, R.L. J. Clin. Invest. (1993) [Pubmed]
  3. Transforming growth factor-beta in human cutaneous leishmaniasis. Barral, A., Teixeira, M., Reis, P., Vinhas, V., Costa, J., Lessa, H., Bittencourt, A.L., Reed, S., Carvalho, E.M., Barral-Netto, M. Am. J. Pathol. (1995) [Pubmed]
  4. SCID mice reconstituted with IL-4-deficient lymphocytes, but not immunocompetent lymphocytes, are resistant to cutaneous leishmaniasis. Satoskar, A., Brombacher, F., Dai, W.J., McInnes, I., Liew, F.Y., Alexander, J., Walker, W. J. Immunol. (1997) [Pubmed]
  5. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Al-Abdely, H.M., Graybill, J.R., Loebenberg, D., Melby, P.C. Antimicrob. Agents Chemother. (1999) [Pubmed]
  6. Allopurinol in the treatment of American cutaneous leishmaniasis. Martinez, S., Marr, J.J. N. Engl. J. Med. (1992) [Pubmed]
  7. Allopurinol in the treatment of American cutaneous leishmaniasis. Herwaldt, B.L., Neva, F.A., Berman, J.D. N. Engl. J. Med. (1992) [Pubmed]
  8. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. Kima, P.E., Constant, S.L., Hannum, L., Colmenares, M., Lee, K.S., Haberman, A.M., Shlomchik, M.J., McMahon-Pratt, D. J. Exp. Med. (2000) [Pubmed]
  9. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. Stenger, S., Donhauser, N., Thüring, H., Röllinghoff, M., Bogdan, C. J. Exp. Med. (1996) [Pubmed]
  10. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. Titus, R.G., Sherry, B., Cerami, A. J. Exp. Med. (1989) [Pubmed]
  11. Occlusive paromomycin for cutaneous leishmaniasis. Bryceson, A.D. Lancet (1997) [Pubmed]
  12. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Ballou, W.R., McClain, J.B., Gordon, D.M., Shanks, G.D., Andujar, J., Berman, J.D., Chulay, J.D. Lancet (1987) [Pubmed]
  13. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Osorio, L.E., Palacios, R., Chica, M.E., Ochoa, M.T. Lancet (1998) [Pubmed]
  14. Herbicides to curb human parasitic infections: in vitro and in vivo effects of trifluralin on the trypanosomatid protozoans. Chan, M.M., Grogl, M., Chen, C.C., Bienen, E.J., Fong, D. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  15. The effect of BCG on experimental cutaneous leishmaniasis in mice. Weintraub, J., Weinbaum, F.I. J. Immunol. (1977) [Pubmed]
  16. The dendritic cell receptor DC-SIGN discriminates among species and life cycle forms of Leishmania. Colmenares, M., Corbí, A.L., Turco, S.J., Rivas, L. J. Immunol. (2004) [Pubmed]
  17. Epidermal compromise in American cutaneous leishmaniasis. Cáceres-Dittmar, G., Sánchez, M.A., Oriol, O., Kraal, G., Tapia, F.J. J. Invest. Dermatol. (1992) [Pubmed]
  18. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Jaser, M.A., el-Yazigi, A., Croft, S.L. Pharm. Res. (1995) [Pubmed]
  19. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Rafati, S., Salmanian, A.H., Taheri, T., Vafa, M., Fasel, N. Vaccine (2001) [Pubmed]
  20. The inducible form of nitric oxide synthase (NOS2) isolated from murine macrophages maps near the nude mutation on mouse chromosome 11. Mock, B.A., Krall, M.M., Byrd, L.G., Chin, H., Barton, C.H., Charles, I., Liew, F.Y., Blackwell, J. Eur. J. Immunogenet. (1994) [Pubmed]
  21. IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/CD40 ligand-dependent process. Marovich, M.A., McDowell, M.A., Thomas, E.K., Nutman, T.B. J. Immunol. (2000) [Pubmed]
  22. Differential expression of chemokines in patients with localized and diffuse cutaneous American leishmaniasis. Ritter, U., Moll, H., Laskay, T., Bröcker, E., Velazco, O., Becker, I., Gillitzer, R. J. Infect. Dis. (1996) [Pubmed]
  23. Antibodies to laminin in American cutaneous leishmaniasis. Avila, J.L., Rojas, M., Rieber, M. Infect. Immun. (1984) [Pubmed]
  24. Indications of the protective role of natural killer cells in human cutaneous leishmaniasis in an area of endemicity. Maasho, K., Sanchez, F., Schurr, E., Hailu, A., Akuffo, H. Infect. Immun. (1998) [Pubmed]
  25. Acute immobilization stress induces clinical and neuroimmunological alterations in experimental murine cutaneous leishmaniasis. Ruiz, M.R., Quiñones, A.G., Díaz, N.L., Tapia, F.J. Br. J. Dermatol. (2003) [Pubmed]
  26. Resistance to Leishmania major in mice. Demant, P., Lipoldova, M., Svobodova, M. Science. (1996) [Pubmed]
  27. Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Lipoldová, M., Demant, P. Nat. Rev. Genet. (2006) [Pubmed]
  28. Resistance to Leishmania major is linked to the H2 region on chromosome 17 and to chromosome 9. Roberts, L.J., Baldwin, T.M., Curtis, J.M., Handman, E., Foote, S.J. J. Exp. Med. (1997) [Pubmed]
  29. Genetics of susceptibility to leishmaniasis in mice: four novel loci and functional heterogeneity of gene effects. Havelková, H., Badalová, J., Svobodová, M., Vojtíková, J., Kurey, I., Vladimirov, V., Demant, P., Lipoldová, M. Genes. Immun. (2006) [Pubmed]
  30. Susceptibility to Leishmania major infection in mice: multiple loci and heterogeneity of immunopathological phenotypes. Lipoldová, M., Svobodová, M., Krulová, M., Havelková, H., Badalová, J., Nohýnková, E., Holán, V., Hart, A.A., Volf, P., Demant, P. Genes. Immun. (2000) [Pubmed]
  31. Distinct genetic control of parasite elimination, dissemination, and disease after Leishmania major infection. Kurey, I., Kobets, T., Havelková, H., Slapnicková, M., Quan, L., Trtková, K., Grekov, I., Svobodová, M., Stassen, A.P., Hutson, A., Demant, P., Lipoldová, M. Immunogenetics. (2009) [Pubmed]
  32. Different genetic control of cutaneous and visceral disease after Leishmania major infection in mice. Vladimirov, V., Badalová, J., Svobodová, M., Havelková, H., Hart, A.A., Blazková, H., Demant, P., Lipoldová, M. Infect. Immun. (2003) [Pubmed]
  33. Chromosomes X, 9, and the H2 locus interact epistatically to control Leishmania major infection. Roberts, L.J., Baldwin, T.M., Speed, T.P., Handman, E., Foote, S.J. Eur. J. Immunol. (1999) [Pubmed]
  34. A Leishmania major response locus identified by interval-specific congenic mapping of a T helper type 2 cell bias-controlling quantitative trait locus. Baguet, A., Epler, J., Wen, K.W., Bix, M. J. Exp. Med. (2004) [Pubmed]
  35. Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice. Beebe, A.M., Mauze, S., Schork, N.J., Coffman, R.L. Immunity. (1997) [Pubmed]
  36. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. Padigel, U.M., Alexander, J., Farrell, J.P. J. Immunol. (2003) [Pubmed]
  37. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Bacellar, O., Lessa, H., Schriefer, A., Machado, P., Ribeiro de Jesus, A., Dutra, W.O., Gollob, K.J., Carvalho, E.M. Infect. Immun. (2002) [Pubmed]
  38. Cytokine interactions in experimental cutaneous leishmaniasis. II. Endogenous tumor necrosis factor-alpha production by macrophages is induced by the synergistic action of interferon (IFN)-gamma and interleukin (IL) 4 and accounts for the antiparasitic effect mediated by IFN-gamma and IL 4. Stenger, S., Solbach, W., Röllinghoff, M., Bogdan, C. Eur. J. Immunol. (1991) [Pubmed]
  39. Interleukin-4-independent acceleration of cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-CTLA4 antibody. Heinzel, F.P., Maier, R.A. Infect. Immun. (1999) [Pubmed]
  40. Tumor necrosis factor alpha (TNF-alpha) and TNF-beta and their receptors in experimental cutaneous leishmaniasis. de Kossodo, S., Grau, G.E., Louis, J.A., Müller, I. Infect. Immun. (1994) [Pubmed]
  41. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. Convit, J., Castellanos, P.L., Ulrich, M., Castés, M., Rondón, A., Pinardi, M.E., Rodríquez, N., Bloom, B.R., Formica, S., Valecillos, L. J. Infect. Dis. (1989) [Pubmed]
  42. Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major. Flohé, S.B., Bauer, C., Flohé, S., Moll, H. Eur. J. Immunol. (1998) [Pubmed]
  43. Successful chemotherapy in experimental leishmaniasis is influenced by the polarity of the T cell response before treatment. Nabors, G.S., Farrell, J.P. J. Infect. Dis. (1996) [Pubmed]
  44. Detection of potentially diagnostic leishmanial antigens by western blot analysis of sera from patients with kala-azar or multilesional cutaneous leishmaniasis. Bogdan, C., Stosiek, N., Fuchs, H., Röllinghoff, M., Solbach, W. J. Infect. Dis. (1990) [Pubmed]
  45. Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis. Rocha, P.N., Almeida, R.P., Bacellar, O., de Jesus, A.R., Filho, D.C., Filho, A.C., Barral, A., Coffman, R.L., Carvalho, E.M. J. Infect. Dis. (1999) [Pubmed]
WikiGenes - Universities